Received: 10.07.2023/ Accepted: 30.11.2023/ Published online: 29.12.2023
УДК 612.176.2 — 612.176.4
DOI 10.53511/PHARMKAZ.2024.56.52.002
M.B. BAURZHAN1, N.S. SAGANDYKOVA2, K.B. ABZALIEV3, K.S. AKHMETOVA3, M.K. MUSIMKHAN3, K.S. ABSATAROVA3
1Academy of Physical Culture and Mass Sports, Astana, Kazakhstan
2Nazarbayev University, Astana, Kazakhstan
3Al-Farabi Kazakh National University, Almaty, Kazakhstan
THE ROLE OF IL1RL1(SST2) IN MYOCARDIAL STRESS AND NON-ADAPTIVE
REMODELING DEVELOPMENT OF HIGH PHYSICAL ACTIVITY INDIVIDUALS
Resume: Sudden cardiac death (SCD) remains one of the most pressing global health problems. The United
States National Young Athlete WBC Registry data show a progressive increase of SCD over the past 2.5
decades, averaging 6% per year. Despite this, there are no SCD statistics in the Republic of Kazakhstan.
To study the early SCD predictors is one of the urgent tasks of modern healthcare. This review discusses
the modern biomarker IL1RL1(ST2) used to diagnose SCD, myocardial fibrosis, and heart failure.
Key words: myocardial fibrosis, sudden cardiac death, diagnostics, biomarker, IL1RL1(ST2).
REFERENCES
1 Deo R., Albert C.M. Epidemiology and genetics of sudden cardiac death. Circulation. 2012;125:620-637. doi: 10.1161/CIRCULATIONAHA.111.023838.
2 Baevskij R. M., Berseneva A. P. Ocenka adaptacionnyh vozmozhnostej organizma i risk razvitija zabolevanij / M.: Medicina, 1997. – 265 s.
3 Gavrilova E.A. Heart rate variability and sports. Human Physiology. 2016;42(5):121-129. http://dx.doi.org/10.7868/S0131164616050088
4 Gorbenko, A., Skirdenko, Ju., Nikolaev, N., Zamahina, O., Sherstjuk, S., & Ershov, A. (2020). Sportivnoe serdce: norma ili patologija. Patologija
krovoobrashhenija i kardiohirurgija, 24(2), 16–25. https://doi.org/10.21688/1681-3472-2020-2-16-25
5 Siegel A.J. Pheidippides redux: reducing risk for acute cardiac events during marathon running. Am J Med. 2012;125(7):630-635. PMID: 22608535. http://
dx.doi.org/10.1016/j.amjmed.2011.11.008
6 Etiology of sudden death in sports: Insights from a United Kingdom Regional Registry / Finocchiaro G, Papadakis M, Robertus J et al. // J Am Col Cardiol.
2016. No 67. P. 2108-2115
7 Mandsager K., Harb S., Cremer P., Phelan D., Nissen S.E., Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing
exercise treadmill testing. JAMA Netw. Open. 2018;1:e183605. doi: 10.1001/jamanetworkopen.2018.3605.
8 Shiroma E.J., Lee I.-M. Physical activity and cardiovascular health: Lessons learned from epidemiological studies across age, gender, and race/ethnicity.
Circulation. 2010;122:743–752. doi: 10.1161/CIRCULATIONAHA.109.914721.
9 Sollazzo F., Palmieri V., Gervasi S.F., Cuccaro F., Modica G., Narducci M.L., Pelargonio G., Zeppilli P., Bianco M. Sudden Cardiac Death in Athletes in Italy during 2019: Internet-based epidemiological research. Medicina. 2021;57:61. doi: 10.3390/medicina57010061
10 Corrado D., Basso C., Pavei A., Michieli P., Schiavon M., Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation
of a preparticipation screening program. JAMA. 2006;296:1593–1601. doi: 10.1001/jama.296.13.1593. [PubMed] [CrossRef] [Google Scholar]
11 van de Schoor FR, Aengevaeren VL, Hopman MT, et al. Myocardial fibrosis in athletes. Mayo Clin Proc. 2016 №91 P.1617‐1631.
12 Mangold S. Kramer U. Franzen E. et al. Detection of cardiovascular disease in elite athletes using cardiac magnetic resonance imaging. Rofo. 2013;185
P.1167-1174
13 Landry C.H., Allan K.S., Connelly K.A., Cunningham K., Morrison L.J., Dorian P. Sudden Cardiac Arrest during Participation in Competitive Sports. N. Engl.
J. Med. 2017;377:1943–1953. doi: 10.1056/NEJMoa1615710.
14 Global hepatitis report, 2017: World Health Organization. (Электронный ресурс). URL: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/
en (дата обращения: 15.04.2017)
15 Sergey Nurk et al. ,The complete sequence of a human genome.Science376,44-53(2022).DOI:10.1126/science.abj6987
16 Pinevich A.A., Vartanyan N.L., Kiseleva L.N., Bode I.I., Krutetskaya I.Yu., Kartashev A.V., Makarov V.E., Poneza T.E., Smirnov I.V., Samoilovich M.P. PD-L1
and PD-L2 gene expression in human glioblastoma cells resistant to chemo- and radiotherapy. Medical Immunology (Russia). 2023;25(3):605-610. https://
doi.org/10.15789/1563-0625-PLA-2693
17 Samoylenko E.S., Kolesnikova N.V., Baklay V.I., Maydannikova E.Yu., Omelchenko E.V. VEGF gene polymorphism in complicated infective endocarditis //
Russian Journal of Infection and Immunity = Infektsiya i immunitet, 2022, vol. 12, no. 5, pp. 938–946. doi: 10.15789/2220- 7619-VGP-1877
18 Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail.
2017; №5(4) Р.280–286.
19 La Gerche A, Rakhit DJ, Claessen G. Exercise and the right ventricle: a potential Achilles’ heel. Cardiovasc Res. 2017;113:1499‐1508.
20 Aengevaeren VL, Van Kimmenade RRJ, Hopman MTE, Van Royen N, Snider JV, Januzzi JL, et al. Exercise-induced Changes in Soluble ST2 Concentrations
in Marathon Runners. Medicine and science in sports and exercise. 2019;51(3):405-10.
21 Dieplinger B, Januzzi JL, Jr., Steinmair M, Gabriel C, Poelz W, Haltmayer M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for
measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta. 2009;409(1-2):33-40.
22 Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor
family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961-6.
23 Dagher, R., Copenhaver, A.M., Besnard, V. et al. IL-33-ST2 axis regulates myeloid cell differentiation and activation enabling effective club cell regeneration.
Nat Commun 11, 4786 (2020). https://doi.org/10.1038/s41467-020-18466-w
24 Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown
DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department
(PRIDE) study. Am J Cardiol. 2005 Apr 15;95(8):948-54. doi: 10.1016/j.amjcard.2004.12.032. PMID: 15820160.
25 Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM, Drum CL. Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure.
Biomedicines. 2023 Mar 15;11(3):917. doi: 10.3390/biomedicines11030917. PMID: 36979896; PMCID: PMC10046491.
26 Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L, Acheampong E, Zhengcan Z, Xiaoyan Q, Yunsheng X, Jingyuan M, Xiumei G, Guanwei F. Biomarkers in
heart failure: the past, current and future. Heart Fail Rev. 2019 Nov;24(6):867-903. doi: 10.1007/s10741-019-09807-z. PMID: 31183637.
27 Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014.
Epub 2013 Jan 9. PMID: 23313577.
28 Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev
Cardiovasc Ther. 2015;13(9):1017-30. doi: 10.1586/14779072.2015.1071664. Epub 2015 Jul 21. PMID: 26198476.
29 Gaggin HK, Januzzi JL Jr. Natriuretic peptides in heart failure and acute coronary syndrome. Clin Lab Med. 2014 Mar;34(1):43-58, vi. doi: 10.1016/j.
cll.2013.11.007. Epub 2014 Jan 14. PMID: 24507786.
30 Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, Sibellas F, Launay JM, Manivet P, Sadoune M, Nouira S, Solal AC, Mebazaa A; Great
network. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol. 2013 Oct
9;168(4):3404-11. doi: 10.1016/j.ijcard.2013.04.164. Epub 2013 May 14. PMID: 23684562.
31 Grakova E.V., Tepljakov A.T., Kop’eva K.V., Ahmedov Sh.D., Ogurkova O.N., Soldatenko M.V. Prognosticheskaja rol’ novogo biomarkera ST2 v ocenke
riska razvitija neblagoprijatnyh serdechno-sosudistyh sobytij u bol’nyh s hronicheskoj serdechnoj nedostatochnost’ju s sohranennnoj i promezhutochnoj frakciej
vybrosa, perenesshih revaskulirizaciju miokarda // Kardiovask.ter. i prof. 2018. T17, T15 S 40-46.
32 Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Halt-mayer M. Increased plasma concentrations of soluble ST2 are pre-dictive for 1-year
mortalit in patients with acute destabilized heart failure // Clin. Chem. 2008. Vol. 54, N4. P 752-756
33 Wu A.H. Biomarker the Natriutretic peptides for Chronic Hert Failure Galaktin-3 and Soluble ST2// EJIFCC.2012. Vol. 23, N.3. P. 98-102.
34 Ojjji D.B., opie L.H., Lecour S., Lacerda L., Relationship between left ventricular geometry and soluble ST2 in a cohor of hypertensive patients // J.Clin.
Hypertens (Greenwich) 2013.Vol. 15, N 12. P. 899-904.
35 Shan R.V., Januzzi J.L.Jr. ST2 a novel remodeling biomarker in acute and chronic heart failure//Curr.Heart Fail.Rep. 2010 Vol. 7 N1 P 9-14.
36 Dyleva Ju.A.,Gruzdeva O.V., Akbasheva O.E., Uchasova E.G., Fedorova N.V., Chernobaj A.G., karetnikova V.N., Kosareva S.N., Kashtalap V.V., Fedorova
T.S., Barbarash O.L. Znachenie stimulirujushhego faktora rosta ST2 i NT-proBNP v ocenke postinfarktnogo remodelirovanija serdca// Ros.kardiol.zhurn.2015.
T. 9, № 1. S. 26-31.Fan S, Hu Y. Integrative analyses of biomarkers and pathways for heart failure. BMC Med Genomics. 2022 Mar 27;15(1):72. doi: 10.1186/
s12920-022-01221-z. PMID: 35346191; PMCID: PMC8962515.
37 Li H, Xiang D, Zhang J, Duan T, Long F, Li A. [Dynamic changes of brain natriuretic peptide concentration and its diagnostic value for heart failure in early
phase of acute myocardial infarction]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jan 30;38(1):112-116. Chinese. doi: 10.3969/j.issn.1673-4254.2018.01.18.
PMID: 33177027; PMCID: PMC6765625.
38 Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial
Infarction (CLARITY-TIMI) 28 trial. Am Heart J. 2005;149(2):227-233.
39 Pascual-Figal D.A., Carrido I.P., Blanco R., Minguela A., Lax A., Ordonez-Llanos J., Bayes-GenisA., Valdes M., Moore S.A., Januzz J.L. Soluble ST2 is a
marker for acute cardiac allograft rejection// Ann. Thorac. Surg. 2011. Vol. 92, N 6.P,2118-2124.
40 Okar S, Kaypakli O, Şahin DY, Koç M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular
paroxysmal atrial fibrillation. Korean Circ J. 2018;48(10):920-9. DOI:10.4070/kcj.2018.0047
41 Aengevaeren VL, Van Kimmenade RRJ, Hopman MTE, Van Royen N, Snider JV, Januzzi JL, et al. Exercise-induced Changes in Soluble ST2 Concentrations
in Marathon Runners. Medicine and science in sports and exercise. 2019;51(3):405-10.
42 Modern approaches for diagnosing transformations of the heart in qualified athletes. Madina Baurzhan, Kuat Abzaliyev Yrysbubu Anvarbekova, Zhanar
Andassova, Salim Berkinbaev. Karashash Absatarova, Carmen Murariu. В журнале Journal of Physical Education and Sport. Годы охвата Scopus: с 2011
по настоящий момент.Процентиль-60. ISSN:2247-8051E-ISSN:2247-806X. Published online: March 31, 2021/(Accepted for publication March 15, 2021)
DOI:10.7752/jpes.2021.02101. Art # 101 pp. 813 – 818/
43 Prognostic value of serum soluble ST2 in professional athletes. Madina Baurzhan, Kuat Abzaliyev, Salim Berkinbaev, Zhanar Andassova, Yrysbubu
Anvarbekova, Karashash Absatarova, Shynar Tanabayeva. В журнал Retos Годы охвата Scopus:с 2016 по настоящий момент. Процентиль-66. Издатель:
Federacion Espanola de Docentes de Educacion Fisica. ISSN:1579-1726E-ISSN:1988-2041
44 Roca E, Nescolarde L, Lupón J, Barallat J, Januzzi JL, Liu P, Cruz Pastor M, Bayes-Genis A. The Dynamics of Cardiovascular Biomarkers in non-Elite
Marathon Runners. J Cardiovasc Transl Res. 2017 Apr;10(2):206-208.
45 Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70. DOI:10.1016/j.cca.2014.09.021
46 Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013
ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force
on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. DOI:10.1016/j.jacc.2013.05.019
47 Maisel, A.S. Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2) / A.S. Maisel, S. Di Somma // European
Heart Journal. – 2016.
48 von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos
DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic
peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. doi: 10.1016/j.jacc.2007.08.012. Epub 2007
Oct 29. PMID: 17996563.
49 Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll
Cardiol. 2019;74(9):1205-17. DOI:10.1016/j.jacc.2019.06.055
50 Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022
Mar;27(2):625-643. doi: 10.1007/s10741-021-10105-w. Epub 2021 Apr 14. PMID: 33852110; PMCID: PMC8898236.
